| Bioactivity | Orphenadrine citrate is an orally active non-competitive NMDA receptor antagonist (crosses the blood-brain barrier) with a Ki of 6.0 μM. Orphenadrine citrate relieves stiffness, pain and discomfort due to muscle strains, sprains or other injuries. Orphenadrine citrate is also used to relieve tremors associated with parkinson's disease. Orphenadrine citrate has good neuroprotective properties, can be used in studies of neurodegenerative diseases[1][2]. |
| Invitro | Orphenadrine citrate (12 µM; 24.5 h) shows neuroprotective effects on 3-NPA-induced neurotoxicity cerebellar granule cells[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Orphenadrine citrate (10, 20, 30 mg/kg; i.p.; once aday for 3 days) reduces 3-NPA-induced mortality in a dose-dependent manner[1].Orphenadrine citrate (30 mg/kg; i.p.; once aday for 3 days) shows activity to against 3-NPA-induced neuronal damage in vivo[1]. Animal Model: |
| Name | Orphenadrine citrate |
| CAS | 4682-36-4 |
| Formula | C24H31NO8 |
| Molar Mass | 461.50 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Pubill D, et al. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Br J Pharmacol. 2001 Feb;132(3):693-702. [2]. Kornhuber J, et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. |
Orphenadrine citrate
CAS: 4682-36-4 F: C24H31NO8 W: 461.50
Orphenadrine citrate is an orally active non-competitive NMDA receptor antagonist (crosses the blood-brain barrier) with
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.